Product Description
NoNO is developing NoNO-42 as a treatment for acute ischemic stroke. (Sourced from: https://www.nonoinc.ca/nono-inc-announces-first-patient-dosed-with-nono-42-in-a-first-in-humans-phase-1-study/)
Mechanisms of Action: PSD95 Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NoNO
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Stroke
Phase 2: Ischemic Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACT-GLOBAL | P3 |
Recruiting |
Stroke |
2034-09-01 |
|
| ACT-42 Trial | P2 |
Recruiting |
Ischemic Stroke |
2026-05-01 |
|
| NoNO42-01 | P1 |
Completed |
Ischemic Stroke |
2023-10-05 |
43% |